摘要:
A security system wherein, when a staff enters a building, a smart card carried by the staff is verified, and staff information inclusive of a staff number and fingerprint information is read from the smart card and is stored temporarily in a temporary storage file. When the staff logs on to a terminal, the fingerprint of the staff is read by a fingerprint input device (LS) and verified with the fingerprint information of the temporary storage file for verification. When the staff leaves the building, the staff number is read from the smart card the staff carries, and the corresponding staff information is erased from the temporary storage file. Security of a security object inside a security zone can be improved.
摘要:
A biometric authentication device has a threat of an attack of pretending to be someone else by such as forgery. The present invention supports a service provider to appropriately decide the level of such threat.A vulnerability verification server 150 is provided in the system, and the vulnerability of each biometric product is centrally managed. A service provider 130 sends the information that specifies the device in which a client terminal 110 executes the biometric authentication to the vulnerability verification server 150, and receives the vulnerability information. The service provider 130 decides whether the service can be provided or not to the client terminal 110 using the vulnerability information that was received.
摘要:
A biometric authentication device has a threat of an attack of pretending to be someone else by such as forgery. The present invention supports a service provider to appropriately decide the level of such threat.A vulnerability verification server 150 is provided in the system, and the vulnerability of each biometric product is centrally managed. A service provider 130 sends the information that specifies the device in which a client terminal 110 executes the biometric authentication to the vulnerability verification server 150, and receives the vulnerability information. The service provider 130 decides whether the service can be provided or not to the client terminal 110 using the vulnerability information that was received.
摘要:
The present invention shortens the time required for watch list verification, and shortens the time required generally for the personal identification processing which includes watch list verification. In a personal identification system, a biometric information watch list comparison function (31) performs a first comparison of first biometric information in a traveler information DB (53), and biometric information on a biometric information watch list (52). Thereafter, a simplified alien immigration examination comparison function (41) performs a second comparison of the first biometric information in the traveler information DB (53), and second biometric information acquired by a biometric information acquisition function (62). As a result of the comparison, in the case where the difference between the time of the first comparison and the current time is within a previously defined time period, a terminal displays a first comparison result, and a second comparison result.
摘要:
The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.
摘要:
A novel adenine compound represented by the formula (1): [wherein R1 is substituted or unsubstituted alkyl, etc., X is oxygen, etc., A1 is 4- to 8-membered substituted or unsubstituted saturated nitrogen-containing heterocycle containing 1 to 2 hetero atom(s) selected from 1 to 2 nitrogen(s), 0 to 1 oxygen and 0 to 1 sulfur, etc., A2 is substituted or unsubstituted 6- to 10-membered aryl, etc., L1 and L2 are independently a straight chain or branched chain alkylene, etc.], or a pharmaceutically acceptable salt thereof, which is useful as a medicament.
摘要:
A service providing system using the biometrics identification without inputting the user ID poses the problem that the consideration of a service is erroneously claimed to the registered user not using the service due to the erroneous identification. According to this invention, the threshold of the value of the degree of similarity for user identification is set strictly for each registered biometrics information of the user in accordance with the declaration of the loss caused by the erroneous identification.
摘要:
The present invention provides compounds of formula (I) wherein R1, Y1, X1, Z1, X2, Y2, A, Y3, n, R and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
摘要:
This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR3 (wherein R3 represents a hydrogen atom or C1-3 alkyl) or the like; R1 represents substituted or unsubstituted alkyl or the like; R2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.
摘要翻译:本发明涉及由通式(I)表示的腺嘌呤衍生物,其互变异构体或其药学上可接受的盐:其中X表示NR 3(其中R 3表示 氢原子或C 1-3烷基)等; R 1表示取代或未取代的烷基等; R 2表示羟基等; Y表示取代或未取代的芳族杂环等。 此外,本发明涉及包含上述衍生物作为活性成分的药物,例如干扰素诱导剂,抗病毒剂,抗癌剂,2型辅助T细胞选择性免疫应答抑制剂,抗过敏剂和免疫应答调节剂。
摘要:
The present invention relates to a pyrazole derivative represented by formula (I) or (II) ##STR1## wherein R.sup.1 is hydrogen C2-C6 alkyl benzyl or phenyl; each of R.sup.2 and R.sup.3 is hydrogen, C1-C6 alkyl or benzyl; each of R.sup.4 and R.sup.5 is hydrogen, C1-C6 alkyl, C3-C6 alkenyl, C3-C8 cycloalkyl, benzyl or phenyl; X is oxygen or sulfur; R.sup.5 is hydrogen, C2-C6 alkyl, C3-C6 alkenyl, C3-C8 cycloalkyl or benzyl when R.sup.1 is benzyl, R.sup.2 is ethyl, R.sup.3 is hydrogen, and R.sup.4 is hydrogen, and its pharmaceutical use.